Alpha Tau Medical Ltd. Ordinary Shares (DRTS) Stock
NASDAQ · DRTS
14.84
Fundamentals
Market cap
$1.34B
Price / Earnings ratio
-14.7x
Price / Sales ratio
N/A
Price / Book ratio
31.0x
Return on assets
-53.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
New Strong Sell Stocks for July 7th
NeutralDRTSJuly 7, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 7th
DRTS

Zacks Investment Research
New Strong Sell Stocks for July 2nd
NeutralDRTSJuly 2, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 2nd
DRTS

MarketBeat
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
NeutralDRTSMay 29, 2026
MarketBeatNeutral
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
DRTS

MarketBeat
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
NeutralDRTSMay 11, 2026
MarketBeatNeutral
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
DRTS
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
127M84M42M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-42.6M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
New Strong Sell Stocks for July 7th
NeutralDRTSJuly 7, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 7th
DRTS

Zacks Investment Research
New Strong Sell Stocks for July 2nd
NeutralDRTSJuly 2, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 2nd
DRTS

MarketBeat
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
NeutralDRTSMay 29, 2026
MarketBeatNeutral
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
DRTS

MarketBeat
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
NeutralDRTSMay 11, 2026
MarketBeatNeutral
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
DRTS

Stocktwits
DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today
NeutralDRTSMay 11, 2026
StocktwitsNeutral
DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today
DRTS

Stocktwits
DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion
NeutralDRTSApril 24, 2026
StocktwitsNeutral
DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion
DRTS

Business Wire
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
NeutralDRTSFebruary 25, 2026
Business WireNeutral
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
DRTS

Zacks Investment Research
New Strong Sell Stocks for January 27th
NeutralDRTSJanuary 27, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for January 27th
DRTS

Zacks Investment Research
New Strong Sell Stocks for January 20th
NeutralDRTSJanuary 20, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for January 20th
DRTS

Business Wire
OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative
NeutralDRTSSeptember 19, 2022
Business WireNeutral
OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative
DRTS
About Alpha Tau Medical Ltd. Ordinary Shares
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
SectorHealthcare
IndustryBiotechnology
Employees121
CEOMr. Uzi Sofer
IPO DateMar 8, 2021
HeadquartersJerusalem, Israel
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Uzi Sofer | CEO & Chairman | 1970 |
| Mr. Raphi Levy | Chief Financial Officer | 1985 |
| Mr. Amnon Gat | Chief Operations Officer | 1975 |
| Mr. Ronen Segal | Chief Technology Officer | 1973 |
| Ms. Rebecca Becker | Vice President of legal | — |
| Ms. Yael Zeiger | Corporate Controller | 1983 |
Fundamentals
Valuation
Market cap$1.34B
Price-to-sales ratioN/A
Price-to-book value30.96
Price-earnings ratio-14.70
Return on Equity-73.00%
Return on SalesN/A
Return on Assets-53.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.04
Income Statement
Average volume635,910
EBITDA$-41.49M
1 year high (52w)$15.79
1 year low (52w)$3.43
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$23.00
Est return
55.93%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +11.5 | -7.3 | +20.5 | +26.8 | +30.1 | -6.7 | +18.4 | +4.2 |



